000299579 001__ 299579
000299579 005__ 20250312112216.0
000299579 0247_ $$2doi$$a10.1016/j.esmoop.2025.104483
000299579 0247_ $$2pmid$$apmid:40056849
000299579 037__ $$aDKFZ-2025-00520
000299579 041__ $$aEnglish
000299579 082__ $$a610
000299579 1001_ $$aDiefenhardt, M.$$b0
000299579 245__ $$aChemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: 5-year results of the CAO/ARO/AIO-12 trial - a general pairwise comparison.
000299579 260__ $$a[London]$$bElsevier$$c2025
000299579 3367_ $$2DRIVER$$aarticle
000299579 3367_ $$2DataCite$$aOutput Types/Journal article
000299579 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1741690505_9173
000299579 3367_ $$2BibTeX$$aARTICLE
000299579 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299579 3367_ $$00$$2EndNote$$aJournal Article
000299579 520__ $$aTotal neoadjuvant treatment (TNT) has been increasingly adopted for multimodal rectal cancer treatment. Here, we present the 5-year results of our CAO/ARO/AIO-12 randomized phase II trial that compared two TNT sequences.Patients were initially randomized 1 : 1 to arm A (induction chemotherapy followed by chemoradiotherapy) or arm B (chemoradiotherapy followed by consolidation chemotherapy) followed by total mesorectal excision surgery. This report on the 5-year results involved a general pairwise comparison (GPC) of the following parameters, ranked as indicated: overall survival, incidence of locoregional recurrence, incidence of distant metastasis, rate of pathological/clinical complete remission, long-term quality of life (at least 24 months after randomization) based on global health assessed by the European Organisation For Research And Treatment Of Cancer Quality of Life Questionnaire Core 30 questionnaire, and incidence of toxicity, ranked by grade, during follow-up.A total of 306 patients were eligible for this analysis. After a median follow-up of 60 months (interquartile range 58-62 months), we found that long-term oncological outcome was comparable in both arms [e.g. 5-year overall survival 85.8% (95% confidence interval 80.2% to 91.8%) in arm A and 84.2% (95% confidence interval 78.2% to 90.5%) in arm B], regardless of whether patients received induction chemotherapy and chemoradiotherapy or chemoradiotherapy and consolidation chemotherapy. The GPC showed no clinically meaningful overall treatment benefit (-1.38%) or win ratio difference (0.97) between the two treatment sequences. The incidence of pathological or sustained clinical complete remission remained higher in patients treated with consolidation chemotherapy after adjusting for long-term outcome between both arms (11% versus 6.5%).Our 5-year GPC confirmed the 3-year findings that chemoradiotherapy followed by consolidation chemotherapy resulted in higher rates of pathological complete remission without compromising oncological outcome, toxicity, or quality of life. The TNT sequence chemoradiotherapy/chemotherapy may be preferred for organ preservation strategies.
000299579 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000299579 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299579 650_7 $$2Other$$aclinical trial
000299579 650_7 $$2Other$$ageneral pairwise comparison
000299579 650_7 $$2Other$$aradiotherapy
000299579 650_7 $$2Other$$arectal cancer
000299579 650_7 $$2Other$$atotal neoadjuvant treatment
000299579 7001_ $$aKosmala, R.$$b1
000299579 7001_ $$aFleischmann, M.$$b2
000299579 7001_ $$0P:(DE-HGF)0$$aMartin, D.$$b3
000299579 7001_ $$aHofheinz, R-D$$b4
000299579 7001_ $$aGhadimi, M.$$b5
000299579 7001_ $$0P:(DE-HGF)0$$aRödel, C.$$b6
000299579 7001_ $$aPolat, B.$$b7
000299579 7001_ $$aFokas, E.$$b8
000299579 773__ $$0PERI:(DE-600)2844985-X$$a10.1016/j.esmoop.2025.104483$$gVol. 10, no. 3, p. 104483 -$$n3$$p104483$$tESMO open$$v10$$x2059-7029$$y2025
000299579 909CO $$ooai:inrepo02.dkfz.de:299579$$pVDB
000299579 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000299579 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000299579 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000299579 9141_ $$y2025
000299579 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bESMO OPEN : 2022$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:18Z
000299579 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:18Z
000299579 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:18Z
000299579 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bESMO OPEN : 2022$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-30
000299579 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-30
000299579 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x0
000299579 980__ $$ajournal
000299579 980__ $$aVDB
000299579 980__ $$aI:(DE-He78)FM01-20160331
000299579 980__ $$aUNRESTRICTED